These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
645 related articles for article (PubMed ID: 14717940)
1. Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis. Pöschel KA; Bucha E; Esslinger HU; Ulbricht K; Nörtersheuser P; Stein G; Nowak G Kidney Int; 2004 Feb; 65(2):666-74. PubMed ID: 14717940 [TBL] [Abstract][Full Text] [Related]
2. The use of PEG-Hirudin in chronic hemodialysis monitored by the Ecarin Clotting Time: influence on clotting of the extracorporeal system and hemostatic parameters. Ulbricht K; Bucha E; Pöschel KA; Stein G; Wolf G; Nowak G Clin Nephrol; 2006 Mar; 65(3):180-90. PubMed ID: 16550749 [TBL] [Abstract][Full Text] [Related]
3. Anticoagulation with r-hirudin in regular haemodialysis with heparin-induced thrombocytopenia (HIT II). The first long-term application of r-hirudin in a haemodialysis patient. Nowak G; Bucha E; Brauns I; Czerwinski R Wien Klin Wochenschr; 1997 May; 109(10):354-8. PubMed ID: 9200807 [TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers. Esslinger HU; Haas S; Maurer R; Lassmann A; Dübbers K; Müller-Peltzer H Thromb Haemost; 1997 May; 77(5):911-9. PubMed ID: 9184402 [TBL] [Abstract][Full Text] [Related]
5. [Prevention of thrombosis with subcutaneous recombinant hirudin in heparin-induced thrombocytopenia type II. A pilot study]. Huhle G; Hoffmann U; Hoffmann I; Harenberg J; Heene DL Dtsch Med Wochenschr; 2000 Jun; 125(22):686-91. PubMed ID: 10874895 [TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamics and pharmacokinetics of polyethylene glycol-hirudin in patients with chronic renal failure. Pöschel KA; Bucha E; Esslinger HU; Nörtersheuser P; Jansa U; Schindler S; Nowak G; Stein G Kidney Int; 2000 Dec; 58(6):2478-84. PubMed ID: 11115081 [TBL] [Abstract][Full Text] [Related]
7. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure]. Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647 [TBL] [Abstract][Full Text] [Related]
8. Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis. Fischer KG; van de Loo A; Böhler J Kidney Int Suppl; 1999 Nov; (72):S46-50. PubMed ID: 10560805 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients. Vanholder R; Camez A; Veys N; Van Loo A; Dhondt AM; Ringoir S Thromb Haemost; 1997 Apr; 77(4):650-5. PubMed ID: 9134637 [TBL] [Abstract][Full Text] [Related]
10. A prospective comparison of three argatroban treatment regimens during hemodialysis in end-stage renal disease. Murray PT; Reddy BV; Grossman EJ; Hammes MS; Trevino S; Ferrell J; Tang I; Hursting MJ; Shamp TR; Swan SK Kidney Int; 2004 Dec; 66(6):2446-53. PubMed ID: 15569338 [TBL] [Abstract][Full Text] [Related]
11. R-hirudin as anticoagulant in regular hemodialysis therapy: finding of therapeutic R-hirudin blood/plasma concentrations and respective dosages. Bucha E; Nowak G; Czerwinski R; Thieler H Clin Appl Thromb Hemost; 1999 Jul; 5(3):164-70. PubMed ID: 10726003 [TBL] [Abstract][Full Text] [Related]
12. Dermatan sulfate: an alternative to unfractionated heparin for anticoagulation in hemodialysis patients. Vitale C; Berutti S; Bagnis C; Soragna G; Gabella P; Fruttero C; Marangella M J Nephrol; 2013; 26(1):158-63. PubMed ID: 22419236 [TBL] [Abstract][Full Text] [Related]
13. Successful use of recombinant hirudin and its monitoring by ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization. Iqbal O; Tobu M; Aziz S; Gerdisch M; Da Valle M; Demir M; Hoppensteadt DA; Ahmad S; Walenga JM; Fareed J J Card Surg; 2005; 20(1):42-51. PubMed ID: 15673409 [TBL] [Abstract][Full Text] [Related]
14. Effects of PEG-hirudin in clotting parameters and platelet function and its interaction with aspirin in healthy volunteers. Esslinger HU; Köhne S; Radziwon P; Walenga JM; Breddin HK Clin Appl Thromb Hemost; 2003 Jan; 9(1):79-88. PubMed ID: 12643328 [TBL] [Abstract][Full Text] [Related]
15. Ecarin clotting time but not aPTT correlates with PEG-hirudin plasma activity. Moser M; Ruef J; Peter K; Kohler B; Gulba DC; Paterna N; Nordt T; Kübler W; Bode C J Thromb Thrombolysis; 2001 Oct; 12(2):165-9. PubMed ID: 11729368 [TBL] [Abstract][Full Text] [Related]
16. The effect of r-hirudin vs. heparin on blood-membrane interactions during hemodialysis. van Wyk V; Badenhorst PN; Kotzé HF Clin Nephrol; 1997 Dec; 48(6):381-7. PubMed ID: 9438098 [TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of single bolus anticoagulation with enoxaparin for chronic hemodialysis. Results of an open-label post-certification study. Klingel R; Schwarting A; Lotz J; Eckert M; Hohmann V; Hafner G Kidney Blood Press Res; 2004; 27(4):211-7. PubMed ID: 15273423 [TBL] [Abstract][Full Text] [Related]
18. Recombinant hirudin anticoagulation for aortic valve replacement in heparin-induced thrombocytopenia. Longrois D; de Maistre E; Bischoff N; Dopff C; Meistelman C; Angioï M; Lecompte T Can J Anaesth; 2000 Mar; 47(3):255-60. PubMed ID: 10730738 [TBL] [Abstract][Full Text] [Related]
19. Variations in the circulating heparin levels during maintenance hemodialysis in patients with end-stage renal disease. Kaneva K; Bansal V; Hoppensteadt D; Cunanan J; Fareed J Clin Appl Thromb Hemost; 2013; 19(4):449-52. PubMed ID: 23463188 [TBL] [Abstract][Full Text] [Related]
20. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Greinacher A; Völpel H; Janssens U; Hach-Wunderle V; Kemkes-Matthes B; Eichler P; Mueller-Velten HG; Pötzsch B Circulation; 1999 Jan 5-12; 99(1):73-80. PubMed ID: 9884382 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]